# Cardinal Health Inc: overview

CAH · NYSE · CIK 721371 · [Consumer discretionary](/sectors/consumer-discretionary.md) · fiscal year ends Jun 30

Pages: [Overview](/companies/cah.md) · [Financials](/companies/cah/financials.md) · [Filings](/companies/cah/filings.md) · [Insiders](/companies/cah/insiders.md)

Latest reported revenue: [$65.63bn](/filings/0000721371-26-000006.md) for Q2 FY2026, three months to 2025-12-31, from the 10-Q filed Feb 5, 2026 (XBRL us-gaap:Revenues, accession 0000721371-26-000006).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $bn | [54.9](/filings/0000721371-25-000038.md) | [59.9 d](/filings/0000721371-26-000038.md) | [52.3](/filings/0000721371-25-000130.md) | [55.3](/filings/0000721371-26-000006.md) | [54.9](/filings/0000721371-25-000038.md) | [60.2 d](/filings/0000721371-26-000038.md) | [64.0](/filings/0000721371-25-000130.md) | [65.6](/filings/0000721371-26-000006.md) |
| Gross margin | % | [3.5%](/filings/0000721371-25-000038.md) | [3.1% d](/filings/0000721371-26-000038.md) | [3.6%](/filings/0000721371-25-000130.md) | [3.5%](/filings/0000721371-26-000006.md) | [3.9%](/filings/0000721371-25-000038.md) | [3.7% d](/filings/0000721371-26-000038.md) | [3.6%](/filings/0000721371-25-000130.md) | [3.7%](/filings/0000721371-26-000006.md) |
| Operating margin | % | [0.7%](/filings/0000721371-25-000038.md) | [0.7% d](/filings/0000721371-26-000038.md) | [1.1%](/filings/0000721371-25-000130.md) | [1.0%](/filings/0000721371-26-000006.md) | [1.3%](/filings/0000721371-25-000038.md) | [0.7% d](/filings/0000721371-26-000038.md) | [1.0%](/filings/0000721371-25-000130.md) | [1.1%](/filings/0000721371-26-000006.md) |
| Net margin | % | [0.5%](/filings/0000721371-25-000038.md) | [0.4% d](/filings/0000721371-26-000038.md) | [0.8%](/filings/0000721371-25-000130.md) | [0.7%](/filings/0000721371-26-000006.md) | [0.9%](/filings/0000721371-25-000038.md) | [0.4% d](/filings/0000721371-26-000038.md) | [0.7%](/filings/0000721371-25-000130.md) | [0.7%](/filings/0000721371-26-000006.md) |
| Diluted EPS | $ per share | [1.07](/filings/0000721371-24-000056.md) | not reported | [1.70](/filings/0000721371-25-000130.md) | not reported | not reported | not reported | [1.88](/filings/0000721371-25-000130.md) | not reported |
| Free cash flow | $bn | [(0.1) d](/filings/0000721371-25-000038.md) | [1.9 d](/filings/0000721371-26-000038.md) | [(1.7)](/filings/0000721371-25-000130.md) | [(0.5) d](/filings/0000721371-26-000006.md) | [2.8 d](/filings/0000721371-25-000038.md) | [1.3 d](/filings/0000721371-26-000038.md) | [0.9](/filings/0000721371-25-000130.md) | [0.6 d](/filings/0000721371-26-000006.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2022 (2022-06-30) | FY2023 (2023-06-30) | FY2024 (2024-06-30) | FY2025 (2025-06-30) | FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $bn | [181](/filings/0000721371-24-000056.md) | [205](/filings/0000721371-25-000079.md) | [227](/filings/0000721371-26-000038.md) | [223](/filings/0000721371-26-000038.md) | [254](/filings/0000721371-26-000038.md) |
| Gross margin | % | [3.6%](/filings/0000721371-24-000056.md) | [3.4%](/filings/0000721371-25-000079.md) | [3.3%](/filings/0000721371-26-000038.md) | [3.7%](/filings/0000721371-26-000038.md) | [3.8%](/filings/0000721371-26-000038.md) |
| Operating margin | % | [(0.3%)](/filings/0000721371-24-000056.md) | [0.4%](/filings/0000721371-25-000079.md) | [0.5%](/filings/0000721371-26-000038.md) | [1.0%](/filings/0000721371-26-000038.md) | [1.0%](/filings/0000721371-26-000038.md) |
| Net margin | % | [(0.5%)](/filings/0000721371-24-000056.md) | [0.2%](/filings/0000721371-25-000079.md) | [0.4%](/filings/0000721371-26-000038.md) | [0.7%](/filings/0000721371-26-000038.md) | [0.7%](/filings/0000721371-26-000038.md) |
| Diluted EPS | $ per share | [(3.37)](/filings/0000721371-24-000056.md) | [1.26](/filings/0000721371-25-000079.md) | [3.45](/filings/0000721371-26-000038.md) | [6.45](/filings/0000721371-26-000038.md) | [7.23](/filings/0000721371-26-000038.md) |
| Free cash flow | $bn | [2.8](/filings/0000721371-24-000056.md) | [2.4](/filings/0000721371-25-000079.md) | [3.3](/filings/0000721371-26-000038.md) | [1.9](/filings/0000721371-26-000038.md) | [4.5](/filings/0000721371-26-000038.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/cah/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $6.29bn | 26,490,633 |  | Reduced −2,004,222 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $3.63bn | 15,292,186 |  | Added +3,477 |
| [WELLINGTON MANAGEMENT GROUP LLP](/funds/902219.md) | 2026-06-30 | $3.53bn | 14,860,271 |  | Added +10,584,119 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $3.26bn | 13,717,894 |  | Reduced −14,415 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $2.84bn | 11,967,121 |  | Reduced −107,397 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $1.53bn | 6,472,810 |  | Reduced −107,722 |
| [Invesco Ltd.](/funds/914208.md) | 2026-06-30 | $1.13bn | 4,742,576 |  | Added +1,230,335 |
| [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $1.10bn | 4,625,329 |  | Reduced −328,999 |
| [WCM INVESTMENT MANAGEMENT, LLC](/funds/1061186.md) | 2026-06-30 | $971.4m | 4,112,461 |  | Added +105,825 |
| [NORGES BANK](/funds/1374170.md) | 2026-06-30 | $885.2m | 3,726,422 |  | New +3,726,422 |

## Recent filings

[All 1,604 filings](/companies/cah/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-01 | 10:52 ET | [8-K](/filings/0000721371-26-000041.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000721371-26-000041 |
| 2026-09-21 | 20:15 ET | [DEF 14A](/filings/0001308179-26-000402.md) | Proxy statement, period 2026-11-12 | 0001308179-26-000402 |
| 2026-08-11 | 12:57 ET | [10-K](/filings/0000721371-26-000038.md) | Annual report, period 2026-06-30 | 0000721371-26-000038 |
| 2026-08-11 | 10:47 ET | [8-K](/filings/0000721371-26-000037.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000721371-26-000037 |
| 2026-08-11 | 10:38 ET | [8-K](/filings/0000721371-26-000036.md) | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0000721371-26-000036 |
| 2026-08-05 | 10:39 ET | [8-K](/filings/0000721371-26-000026.md) | 5.02 Departure or appointment of officers or directors | 0000721371-26-000026 |
| 2026-04-30 | 12:51 ET | [10-Q](/filings/0000721371-26-000018.md) | Quarterly report, period 2026-03-31 | 0000721371-26-000018 |
| 2026-04-30 | 10:47 ET | [8-K](/filings/0000721371-26-000017.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000721371-26-000017 |
| 2026-03-23 | 10:48 ET | [8-K](/filings/0000721371-26-000013.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000721371-26-000013 |
| 2026-03-05 | 12:07 ET | [8-K](/filings/0000721371-26-000010.md) | 5.02 Departure or appointment of officers or directors | 0000721371-26-000010 |

## Latest annual report

[Form 10-K for the fiscal year ended Jun 30, 2026](/filings/0000721371-26-000038.md), filed Aug 11, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 721371
- Tickers: CAH
- Exchange: NYSE
- SIC code: 5122 Wholesale-Drugs, Proprietaries & Druggists' Sundries
- State of incorporation: OH
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:23 ET. No prices; not investment advice.